(AKZA) Akzo Nobel - Ratings and Ratios

Exchange: AS • Country: Netherlands • Currency: EUR • Type: Common Stock • ISIN: NL0013267909

Paints, Coatings, Varnishes, Lacquers, Specialty Chemicals

AKZA EPS (Earnings per Share)

EPS (Earnings per Share) of AKZA over the last years for every Quarter: "2020-09": 1.3, "2020-12": 1.08, "2021-03": 1.18, "2021-06": 1.2, "2021-09": 0.93, "2021-12": 0.74, "2022-03": 0.86, "2022-06": 0.84, "2022-09": 0.57, "2022-12": 0.16, "2023-03": 0.73, "2023-06": 0.93, "2023-09": 0.99, "2023-12": 0.42, "2024-03": 1.12, "2024-06": 1.07, "2024-09": 0.95, "2024-12": 0.56, "2025-03": 0.94, "2025-06": 0.73,

AKZA Revenue

Revenue of AKZA over the last years for every Quarter: 2020-09: 2276, 2020-12: 2209, 2021-03: 2263, 2021-06: 2511, 2021-09: 2410, 2021-12: 2403, 2022-03: 2525, 2022-06: 2853, 2022-09: 2862, 2022-12: 2606, 2023-03: 2657, 2023-06: 2741, 2023-09: 2741, 2023-12: 2529, 2024-03: 2640, 2024-06: 2784, 2024-09: 2668, 2024-12: 2619, 2025-03: 2613, 2025-06: 2626,

Description: AKZA Akzo Nobel

Akzo Nobel NV is a global paints and coatings company operating in two main segments: Decorative Paints and Performance Coatings. The company offers a wide range of products, including paints, lacquers, varnishes, and powder coatings, under various brands such as Dulux, Sikkens, and International. Akzo Nobel serves various industries, including energy, packaging, infrastructure, and shipbuilding, as well as general industries like agricultural and construction equipment.

From a financial perspective, Akzo Nobel has a market capitalization of approximately €10.1 billion, indicating a significant presence in the specialty chemicals sector. The companys return on equity (RoE) stands at 10.26%, suggesting a decent level of profitability. To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio can be examined. For instance, a stable EBITDA margin would indicate the companys ability to maintain profitability, while a manageable debt-to-equity ratio would suggest a healthy capital structure.

To gain a deeper understanding of Akzo Nobels competitive position, its essential to analyze its market share, brand portfolio, and product offerings. The companys diverse brand portfolio and wide range of products enable it to cater to various customer needs. Additionally, Akzo Nobels presence in multiple industries and geographies provides a degree of diversification, potentially reducing its dependence on any single market. Key metrics such as sales growth, market share, and customer satisfaction can help assess the companys competitive strength.

From an investment perspective, Akzo Nobels stock has a forward price-to-earnings (P/E) ratio of 14.47, which can be compared to industry averages to determine if the stock is undervalued or overvalued. Other relevant metrics, such as dividend yield and payout ratio, can also be examined to assess the stocks attractiveness. For example, a stable dividend yield and a reasonable payout ratio may indicate a attractive investment opportunity.

AKZA Stock Overview

Market Cap in USD 11,983m
Sub-Industry Specialty Chemicals
IPO / Inception

AKZA Stock Ratings

Growth Rating 0.08%
Fundamental 51.6%
Dividend Rating 42.2%
Return 12m vs S&P 500 -11.8%
Analyst Rating -

AKZA Dividends

Dividend Yield 12m 3.24%
Yield on Cost 5y 2.52%
Annual Growth 5y 0.77%
Payout Consistency 90.6%
Payout Ratio 62.3%

AKZA Growth Ratios

Growth Correlation 3m 71.2%
Growth Correlation 12m 56.1%
Growth Correlation 5y -77.1%
CAGR 5y -0.83%
CAGR/Max DD 3y (Calmar Ratio) -0.02
CAGR/Mean DD 3y (Pain Ratio) -0.06
Sharpe Ratio 12m -0.15
Alpha -14.78
Beta 1.036
Volatility 20.03%
Current Volume 415.4k
Average Volume 20d 344.8k
Stop Loss 59.2 (-3.1%)
Signal 0.56

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (415.0m TTM) > 0 and > 6% of Revenue (6% = 631.6m TTM)
FCFTA 0.03 (>2.0%) and ΔFCFTA -1.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 11.10% (prev 5.16%; Δ 5.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 814.0m > Net Income 415.0m (YES >=105%, WARN >=100%)
Net Debt (3.77b) to EBITDA (1.17b) ratio: 3.23 <= 3.0 (WARN <= 3.5)
Current Ratio 1.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (171.0m) change vs 12m ago 0.12% (target <= -2.0% for YES)
Gross Margin 39.85% (prev 40.90%; Δ -1.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 73.47% (prev 73.83%; Δ -0.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 4.42 (EBITDA TTM 1.17b / Interest Expense TTM 179.0m) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 51.57

1. Piotroski 2.50pt = -2.50
2. FCF Yield 3.48% = 1.74
3. FCF Margin 4.56% = 1.14
4. Debt/Equity 1.22 = 1.80
5. Debt/Ebitda 3.23 = -2.06
6. ROIC - WACC (= 1.25)% = 1.56
7. RoE 9.25% = 0.77
8. Rev. Trend -39.59% = -2.97
9. EPS Trend 41.63% = 2.08

What is the price of AKZA shares?

As of October 17, 2025, the stock is trading at EUR 61.10 with a total of 415,428 shares traded.
Over the past week, the price has changed by +1.73%, over one month by +0.39%, over three months by +3.31% and over the past year by +1.27%.

Is Akzo Nobel a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Akzo Nobel is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 51.57 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AKZA is around 59.12 EUR . This means that AKZA is currently overvalued and has a potential downside of -3.24%.

Is AKZA a buy, sell or hold?

Akzo Nobel has no consensus analysts rating.

What are the forecasts/targets for the AKZA price?

Issuer Target Up/Down from current
Wallstreet Target Price 69.4 13.6%
Analysts Target Price - -
ValueRay Target Price 65 6.3%

AKZA Fundamental Data Overview

Market Cap USD = 11.98b (10.27b EUR * 1.1665 EUR.USD)
Market Cap EUR = 10.27b (10.27b EUR * 1.0 EUR.EUR)
P/E Trailing = 25.025
P/E Forward = 13.4409
P/S = 0.9759
P/B = 2.4845
P/EG = 1.0134
Beta = 1.036
Revenue TTM = 10.53b EUR
EBIT TTM = 792.0m EUR
EBITDA TTM = 1.17b EUR
Long Term Debt = 3.47b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.61b EUR (from shortLongTermDebt, last fiscal year)
Debt = 5.08b EUR (Calculated: Short Term 1.61b + Long Term 3.47b)
Net Debt = 3.77b EUR (from netDebt column, last fiscal year)
Enterprise Value = 13.80b EUR (10.27b + Debt 5.08b - CCE 1.55b)
Interest Coverage Ratio = 4.42 (Ebit TTM 792.0m / Interest Expense TTM 179.0m)
FCF Yield = 3.48% (FCF TTM 480.0m / Enterprise Value 13.80b)
FCF Margin = 4.56% (FCF TTM 480.0m / Revenue TTM 10.53b)
Net Margin = 3.94% (Net Income TTM 415.0m / Revenue TTM 10.53b)
Gross Margin = 39.85% ((Revenue TTM 10.53b - Cost of Revenue TTM 6.33b) / Revenue TTM)
Gross Margin QoQ = 39.53% (prev 40.11%)
Tobins Q-Ratio = 0.97 (Enterprise Value 13.80b / Total Assets 14.17b)
Interest Expense / Debt = 1.34% (Interest Expense 68.0m / Debt 5.08b)
Taxrate = 24.58% (44.0m / 179.0m)
NOPAT = 597.3m (EBIT 792.0m * (1 - 24.58%))
Current Ratio = 1.23 (Total Current Assets 6.33b / Total Current Liabilities 5.16b)
Debt / Equity = 1.22 (Debt 5.08b / totalStockholderEquity, last quarter 4.17b)
Debt / EBITDA = 3.23 (Net Debt 3.77b / EBITDA 1.17b)
Debt / FCF = 7.86 (Net Debt 3.77b / FCF TTM 480.0m)
Total Stockholder Equity = 4.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.93% (Net Income 415.0m / Total Assets 14.17b)
RoE = 9.25% (Net Income TTM 415.0m / Total Stockholder Equity 4.49b)
RoCE = 9.95% (EBIT 792.0m / Capital Employed (Equity 4.49b + L.T.Debt 3.47b))
RoIC = 8.16% (NOPAT 597.3m / Invested Capital 7.32b)
WACC = 6.91% (E(10.27b)/V(15.35b) * Re(9.83%) + D(5.08b)/V(15.35b) * Rd(1.34%) * (1-Tc(0.25)))
Discount Rate = 9.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.26%
[DCF Debug] Terminal Value 62.83% ; FCFE base≈557.6m ; Y1≈366.1m ; Y5≈167.4m
Fair Price DCF = 14.70 (DCF Value 2.51b / Shares Outstanding 171.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 41.63 | EPS CAGR: 9.41% | SUE: -0.63 | # QB: 0
Revenue Correlation: -39.59 | Revenue CAGR: -3.08% | SUE: -0.97 | # QB: 0

Additional Sources for AKZA Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle